Cyclerion Therapeutics Stock (NASDAQ:CYCN)


RevenueOwnershipFinancialsChart

Previous Close

$1.76

52W Range

$1.71 - $5.25

50D Avg

$2.66

200D Avg

$2.88

Market Cap

$5.66M

Avg Vol (3M)

$213.46K

Beta

1.92

Div Yield

-

CYCN Company Profile


Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

Mar 18, 2019

Website

CYCN Performance


CYCN Financial Summary


Dec 23Dec 22Dec 21
Revenue-$297.00K$3.32M
Operating Income$-12.95M$-44.37M$-55.20M
Net Income$-5.26M$-43.78M$-51.66M
EBITDA$-12.95M$-44.31M$-53.84M
Basic EPS$-2.25$-1.44$-26.40
Diluted EPS$-2.25$-1.44$-26.40

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
ZVSAZyVersa Therapeutics, Inc.
MGTADianthus Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
CFRXContraFect Corporation
AXLAAxcella Health Inc.
MNPRMonopar Therapeutics Inc.
ACHLAchilles Therapeutics plc
LRMRLarimar Therapeutics, Inc.
ERASErasca, Inc.
FENCFennec Pharmaceuticals Inc.
SGTXSigilon Therapeutics, Inc.
KRONKronos Bio, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
LIPOLipella Pharmaceuticals Inc.
ADXNAddex Therapeutics Ltd
KZRKezar Life Sciences, Inc.
FBRXForte Biosciences, Inc.
CDIOCardio Diagnostics Holdings, Inc.